CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.

UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

Cigna is rolling out another weight-loss drug initiative to bolster access to the popular medications and tap more deeply into the booming market. The company's Evernorth Health Services ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Working closely with internal teams, the students gain firsthand insight into real-world applications, fostering a startup ...

Cigna and Evernorth Cigna and Evernorth Therapists in Cherokee Triangle, Louisville, KY Female Male In Person Online All Filters Cigna and Evernorth ...

Express Scripts by Evernorth, the pharmacy benefits business of The Cigna Group, and its affiliated pharmacies, filed a ...

The pharmacy benefit manager (PBM) industry is under pressure to shift to models that avoid conflicts of interest and ...

While Cigna would not discuss the actual discounts reached under the new Evernorth arrangement, analysts say large employers and other insurers have gotten between 30% to 50% below the drugs' list ...